Otsuka reports solid US growth for Abilify
This article was originally published in Scrip
US net sales of the atypical antipsychotic Abilify (aripiprazole) were $3.51 billion in calendar 2010, a 6% increase in local currency terms, new unaudited figures released by originator Otsuka Holdings show.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.